aibioContext Therapeutics sells 14,705,882 shares for about $15 million to MPM BioImpact
Tickers CNTX
The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.
Key facts
- Company
- Context Therapeutics Inc. (NASDAQ: CNTX)
- News type
- Financings
- Primary source
- Context Therapeutics Inc. 8-K (2024-12-23)
Context Therapeutics Inc. sold 14,705,882 shares of its common stock on December 23, 2024, for aggregate gross proceeds of approximately $15 million, according to a Form 8-K filing. Gross proceeds are the amount raised before fees and expenses are deducted.
The Philadelphia company sold the shares under a sales agreement with Leerink Partners LLC dated December 2, 2024. Leerink acted as the company's agent for the sale.
According to the filing, the agent informed the company that the shares were purchased by MPM BioImpact LLC.
The company reported the sale under Item 8.01 of Form 8-K, the section used for other events, and filed the report on the same day the shares were sold. Context Therapeutics' common stock, par value $0.001 per share, trades on The Nasdaq Stock Market under the symbol CNTX. The company identifies itself in the filing as an emerging growth company.